sentence1
stringlengths 35
423
| sentence2
stringlengths 34
427
| score
int64 -1
1
|
|---|---|---|
The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | There is no evidence that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | 0 |
The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | The evidence available, however, suggests that at 12 months, T&E may be comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | 1 |
Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and PRN dosing for both efficacy and safety outcomes when using ranibizumab. | -1 |
Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | The evidence available, however, suggests that at 12 months, T&E is comparable to monthly and inferior to PRN dosing for both efficacy and safety outcomes when using ranibizumab. | -1 |
Combining topical NSAIDs and anti-VEGF agents may provide a new strategy for AMD treatment. | Combining topical NSAIDs and anti-VEGF agents may not provide a new strategy for AMD treatment. | -1 |
Combining topical NSAIDs and anti-VEGF agents may provide a new strategy for AMD treatment. | There is no evidence that combining topical NSAIDs and anti-VEGF agents may provide a new strategy for AMD treatment. | 0 |
Combining topical NSAIDs and anti-VEGF agents may provide a new strategy for AMD treatment. | Combining topical NSAIDs and anti-VEGF agents provides a new strategy for AMD treatment. | 1 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | Vitrectomy does not produce structural and functional improvements in select eyes with diabetic macular edema, and the visual gains are not significantly better than with laser or observation. | -1 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | There is no evidence that vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | 0 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | Vitrectomy may produce structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | 1 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, and the visual gains are significantly better than with laser or observation. | -1 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly worse than with laser or observation. | -1 |
Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains are not significantly better than with laser or observation. | Vitrectomy produces structural and functional improvements in select eyes with diabetic macular edema, but the visual gains may not be significantly better than with laser or observation. | 1 |
Tight glycemic and blood pressure control reduces the incidence and progression of DR. | Tight glycemic and blood pressure control does not reduce the incidence and progression of DR. | -1 |
Tight glycemic and blood pressure control reduces the incidence and progression of DR. | Tight glycemic and blood pressure control increases the incidence and progression of DR. | -1 |
Tight glycemic and blood pressure control reduces the incidence and progression of DR. | There is no evidence that tight glycemic and blood pressure control reduces the incidence and progression of DR. | 0 |
Tight glycemic and blood pressure control reduces the incidence and progression of DR. | Tight glycemic and blood pressure control may reduce the incidence and progression of DR. | 1 |
This meta-analysis summarizes the strong evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. | This meta-analysis summarizes the strong evidence for absence of association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. | -1 |
This meta-analysis summarizes the strong evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. | This meta-analysis summarizes the evidence for an association between CFH and AMD and indicates a multiplicative model with each C allele increasing the odds of AMD by approximately 2.5-fold. | 1 |
There was no association between anti-VEGF injections and RNFL thickness changes when all studies were examined together. | There was an association between anti-VEGF injections and RNFL thickness changes when all studies were examined together. | -1 |
However, when two low-biased, controlled clinical trials were separately examined, repeated anti-VEGF injection was associated with RNFL loss. | However, when two low-biased, controlled clinical trials were separately examined, repeated anti-VEGF injection was not associated with RNFL loss. | -1 |
Bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. | There is no evidence that bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. | 0 |
Bevacizumab and ranibizumab had equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. | Bevacizumab and ranibizumab might have equivalent efficacy for best-corrected visual acuity in the treatment of neovascular age-related macular degeneration. | 1 |
In people with cataracts and generally mild to moderate OAG, there is moderate-certainty evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, likely increases the proportion of participants who do not require IOP lowering medication, and may further reduce IOP at short- and medium-term follow-up. | In people with cataracts and generally mild to moderate OAG, there is moderate-certainty evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, does not likely increase the proportion of participants who do not require IOP lowering medication, and may further reduce IOP at short- and medium-term follow-up. | -1 |
In people with cataracts and generally mild to moderate OAG, there is moderate-certainty evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, likely increases the proportion of participants who do not require IOP lowering medication, and may further reduce IOP at short- and medium-term follow-up. | In people with cataracts and generally mild to moderate OAG, there is moderate-certainty evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, likely decreases the proportion of participants who do not require IOP lowering medication, and may further reduce IOP at short- and medium-term follow-up. | -1 |
In people with cataracts and generally mild to moderate OAG, there is moderate-certainty evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, likely increases the proportion of participants who do not require IOP lowering medication, and may further reduce IOP at short- and medium-term follow-up. | In people with cataracts and generally mild to moderate OAG, there is no evidence that the Hydrus microstent with cataract surgery compared to cataract surgery alone, increases the proportion of participants who do not require IOP lowering medication, and further reduces IOP at short- and medium-term follow-up. | 0 |
There is moderate-certainty evidence that the Hydrus microstent is probably more effective than the iStent in lowering IOP of people with OAG in the short-term. | There is moderate-certainty evidence that the Hydrus microstent is probably not more effective than the iStent in lowering IOP of people with OAG in the short-term. | -1 |
There is moderate-certainty evidence that the Hydrus microstent is probably more effective than the iStent in lowering IOP of people with OAG in the short-term. | There is moderate-certainty evidence that the Hydrus microstent is probably less effective than the iStent in lowering IOP of people with OAG in the short-term. | -1 |
There is moderate-certainty evidence that the Hydrus microstent is probably more effective than the iStent in lowering IOP of people with OAG in the short-term. | There is no evidence that the Hydrus microstent is more effective than the iStent in lowering IOP of people with OAG in the short-term. | 0 |
There is moderate-certainty evidence that the Hydrus microstent is probably more effective than the iStent in lowering IOP of people with OAG in the short-term. | There is evidence that the Hydrus microstent may be more effective than the iStent in lowering IOP of people with OAG in the short-term. | 1 |
Complications may be rare using the Hydrus microstent, as well as the comparator iStent, but larger studies are needed to investigate its safety. | Complications may be more frequent using the Hydrus microstent than the comparator iStent, but larger studies are needed to investigate its safety. | -1 |
SLT was associated with relatively higher efficacy of IOP lowering compared with ALT. | SLT was not associated with relatively higher efficacy of IOP lowering compared with ALT. | -1 |
SLT was associated with relatively higher efficacy of IOP lowering compared with ALT. | SLT was associated with relatively lower efficacy of IOP lowering compared with ALT. | -1 |
SLT was associated with relatively higher efficacy of IOP lowering compared with ALT. | There is no evidence that SLT was associated with relatively higher efficacy of IOP lowering compared with ALT. | 0 |
SLT was associated with relatively higher efficacy of IOP lowering compared with ALT. | SLT might be associated with relatively higher efficacy of IOP lowering compared with ALT. | 1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT does not result in a larger reduction of number of glaucoma medications versus ALT, but it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | -1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT results in a smaller reduction of number of glaucoma medications versus ALT, but it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | -1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | There is no evidence that SLT results in a larger reduction of number of glaucoma medications versus ALT, but it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | 0 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT may result in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | 1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT results in a larger reduction of number of glaucoma medications versus ALT, but it appeared not to be more effective for patients who did not respond adequately to previous laser treatment. | -1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT results in a larger reduction of number of glaucoma medications versus ALT, but it appeared to be less effective for patients who did not respond adequately to previous laser treatment. | -1 |
SLT results in a larger reduction of number of glaucoma medications versus ALT, and it appeared to be more effective for patients who did not respond adequately to previous laser treatment. | SLT results in a larger reduction of number of glaucoma medications versus ALT, and it is more effective for patients who did not respond adequately to previous laser treatment. | 1 |
The difference in tolerability of the 2 lasers was not significant. | The difference in tolerability of the 2 lasers was significant. | -1 |
The difference in tolerability of the 2 lasers was not significant. | There is no evidence that the difference in tolerability of the 2 lasers is significant. | 0 |
The difference in tolerability of the 2 lasers was not significant. | The difference in tolerability of the 2 lasers might not be significant. | 1 |
This meta-analysis suggests that patients with OAG may have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | This meta-analysis suggests that patients with OAG may not have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | -1 |
This meta-analysis suggests that patients with OAG may have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | This meta-analysis suggests that patients with OAG may have lower TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | -1 |
This meta-analysis suggests that patients with OAG may have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | There is no evidence that patients with OAG have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | 0 |
This meta-analysis suggests that patients with OAG may have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | This meta-analysis suggests that patients with OAG have higher TNF-α levels compared with the control subjects, and the TNF-α -308G/A polymorphism is significantly associated with the risks of high-tension glaucoma. | 1 |
EX-PRESS implantation and trabeculectomy have similar efficacy in IOP-lowering, medication reduction, vision recovery, and qualified operative success rates. | There is no evidence that EX-PRESS implantation and trabeculectomy have similar efficacy in IOP-lowering, medication reduction, vision recovery, and qualified operative success rates. | 0 |
EX-PRESS implantation and trabeculectomy have similar efficacy in IOP-lowering, medication reduction, vision recovery, and qualified operative success rates. | EX-PRESS implantation and trabeculectomy may have similar efficacy in IOP-lowering, medication reduction, vision recovery, and qualified operative success rates. | 1 |
EX-PRESS associated with higher rates of complete operative success and fewer hyphema than with Trabeculectomy. However, these should be interpreted with caution because of the inherent limitations of the included studies. | EX-PRESS was not associated with higher rates of complete operative success and fewer hyphema than with Trabeculectomy. However, these should be interpreted with caution because of the inherent limitations of the included studies. | -1 |
EX-PRESS associated with higher rates of complete operative success and fewer hyphema than with Trabeculectomy. However, these should be interpreted with caution because of the inherent limitations of the included studies. | EX-PRESS associated with lower rates of complete operative success and more hyphema than with Trabeculectomy. However, these should be interpreted with caution because of the inherent limitations of the included studies. | -1 |
The existing data in the literature do not support a significant role of WDR36 in the genetic susceptibility of POAG or its subtypes. | The existing data in the literature support a significant role of WDR36 in the genetic susceptibility of POAG or its subtypes. | -1 |
We found no significant relationship between AMD and incident stroke. | We found a significant relationship between AMD and incident stroke. | -1 |
NTG is not associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | NTG is associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | -1 |
NTG is not associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | There is no evidence that NTG is associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | 0 |
NTG is not associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | NTG may not be associated with elevated plasma tHcy, serum folic acid, serum vitamin B12, serum vitamin B6, and MTHFR C677T genotype. | 1 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | The available evidence suggests that dietary lutein may not be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | -1 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | The available evidence suggests that dietary lutein may be harmful to AMD patients and the higher dose could make MPOD increase in a shorter time. | -1 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | There is no evidence that dietary lutein is beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | 0 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | The available evidence suggests that dietary lutein is beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | 1 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD decrease in a shorter time. | -1 |
The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose could make MPOD increase in a shorter time. | The available evidence suggests that dietary lutein may be beneficial to AMD patients and the higher dose can make MPOD increase in a shorter time. | 1 |
Evidence from currently available RCTs is insufficient to conclude that statins have a role in preventing or delaying the onset or progression of AMD. | Evidence from currently available RCTs is sufficient to conclude that statins have a role in preventing or delaying the onset or progression of AMD. | 0 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction does not lower IOP but reduces the dependency on glaucoma medications. | -1 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction does increase IOP, and reduces the dependency on glaucoma medications. | -1 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | There is no evidence that iStent implantation as a solo procedure without concurrent cataract extraction lowers IOP, and reduces the dependency on glaucoma medications. | 0 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction may lower IOP, and reduces the dependency on glaucoma medications. | 1 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP but does not reduce the dependency on glaucoma medications. | -1 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP but increases the dependency on glaucoma medications. | -1 |
iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and reduces the dependency on glaucoma medications. | iStent implantation as a solo procedure without concurrent cataract extraction does lower IOP, and may reduce the dependency on glaucoma medications. | 1 |
Latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | Latanoprost does not provide greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | -1 |
Latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | Latanoprost provides lower IOP-lowering efficacy than timolol in the treatment of patients with CACG. | -1 |
Latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | There is no evidence that latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | 0 |
Latanoprost provides greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | Latanoprost may provide greater IOP-lowering efficacy than timolol in the treatment of patients with CACG. | 1 |
Latanoprost caused conjunctival hyperemia in more patients than timolol. | Latanoprost did not cause conjunctival hyperemia in more patients than timolol. | -1 |
Latanoprost caused conjunctival hyperemia in more patients than timolol. | Latanoprost caused conjunctival hyperemia in less patients than timolol. | -1 |
Latanoprost caused conjunctival hyperemia in more patients than timolol. | There is no evidence that latanoprost caused conjunctival hyperemia in more patients than timolol. | 0 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is not more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | -1 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is less cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | -1 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | There is no evidence that V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | 0 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT may be more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | 1 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely not more cost effective than V-PDT. | -1 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely less cost effective than V-PDT. | -1 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is more cost effective than conventional macular laser, and there is no evidence that pegaptanib is more cost effective than V-PDT. | 0 |
In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is likely more cost effective than V-PDT. | In general, V-PDT is more cost effective than conventional macular laser, and pegaptanib is more cost effective than V-PDT. | 1 |
Although ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | Although ranibizumab is not effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | -1 |
Although ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | Although ranibizumab is ineffective for wet AMD, its cost is unacceptably high based on cost-utility theory. | -1 |
Although ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | Although there is no evidence that ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | 0 |
Although ranibizumab is effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | Although ranibizumab may be effective for wet AMD, its cost is unacceptably high based on cost-utility theory. | 1 |
According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | According to available data, the use of latanoprost is not associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | -1 |
According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | According to available data, the use of latanoprost is associated with a higher incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | -1 |
According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | There is no evidence that the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | 0 |
According to available data, the use of latanoprost is associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | According to available data, the use of latanoprost may be associated with a lower incidence of conjunctival hyperaemia when compared with travoprost and bimatoprost in the treatment of patients with ocular hypertension or glaucoma. | 1 |
Latanoprost, travoprost, and bimatoprost provide significant IOP-lowering efficacy in eyes with CACG; and the 3 prostaglandin analogs are associated with at least as effective as timolol. | Latanoprost, travoprost, and bimatoprost do not provide significant IOP-lowering efficacy in eyes with CACG; and the 3 prostaglandin analogs are associated with at least as effective as timolol. | -1 |
Latanoprost, travoprost, and bimatoprost provide significant IOP-lowering efficacy in eyes with CACG; and the 3 prostaglandin analogs are associated with at least as effective as timolol. | Latanoprost, travoprost, and bimatoprost may provide significant IOP-lowering efficacy in eyes with CACG; and the 3 prostaglandin analogs are associated with at least as effective as timolol. | 1 |
This meta-analysis showed no association between the A alleles of the TNF-α -308 A/G or -238 A/G polymorphisms and glaucoma. | This meta-analysis showed association between the A alleles of the TNF-α -308 A/G or -238 A/G polymorphisms and glaucoma. | -1 |
HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism play important roles in AMD. | HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism do not play important roles in AMD. | -1 |
HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism play important roles in AMD. | There is no evidence that HTRA1 rs11200638 G→A polymorphism and LOC387715/ARMS2 rs10490924 G→T polymorphism play important roles in AMD. | 0 |